

How Nursing Intervention Can Facilitate Clinical Outcomes

References:

1. Burke MJ, Rheingold SR. Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia. *Leuk Lymphoma*. 2017 Mar;58(3):540-551.
2. Burke MJ, Zalewska-Szewczyk B. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences. *Future Oncol*. 2022 Mar;18(10):1285-1299.
3. Cooper SL, Young DJ, Bowen CJ, Arwood NM, Poggi SG, Brown PA. Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions. *Pediatr Blood Cancer*. 2019 Aug;66(8):e27797.
4. Steiner M, Attarbaschi A, Kastner U, et al. Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia. *Pediatr Blood Cancer*. 2007 Oct 15;49(5):640-642.
5. Maese L, Rau RE. Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. *Front Pediatr*. 2022 Jun 30;10:902117.
6. Schulte R, Hinson A, Huynh V, et al. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. *Cancer Med*. 2021 Nov;10(21):7551-7560.

Provided by MediCom Worldwide, Inc.

Supported by an independent medical education grant from Jazz Pharmaceuticals.